Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

Full Year and Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025 Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statemen ...

Core Insights - AstraZeneca reported revenue of $14.89 billion for the quarter ended December 2024, reflecting a 23.8% increase year-over-year and a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion [1] - The earnings per share (EPS) for the quarter was $1.05, compared to $0.73 in the same quarter last year, although it fell short of the consensus EPS estimate of $1.07 by -1.87% [1] Financial Performance Metrics - AstraZeneca's stock has returned +6.5% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change, and currently holds a Zacks Rank 3 (Hold) [3] - Key product performance includes: - Symbicort in the U.S. generated $299 million, exceeding the average estimate of $235.06 million [4] - Oncology product Tagrisso in the U.S. reported $767 million, surpassing the estimated $709.65 million [4] - Collaboration revenue totaled $815 million, significantly above the average estimate of $419.12 million, marking a +68.4% change year-over-year [4] - Oncology product Tagrisso worldwide achieved $1.70 billion, compared to the estimated $1.68 billion, representing a +20% increase year-over-year [4] - BioPharmaceuticals product Farxiga worldwide reported $1.93 billion, slightly below the estimate of $1.96 billion, but still showing a +20.4% year-over-year change [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company engaged in insurance fraud in China, leading to legal exposure and potential harm to its business activities in the region [1]. Group 1: Allegations and Legal Context - The class period for the allegations is from February 23, 2022, to December 17, 2024 [1]. - Allegations include that AstraZeneca issued materially false and misleading statements and failed to disclose its involvement in insurance fraud in China [1]. - The lawsuit claims that the legal exposure faced by AstraZeneca in China resulted in the detention of the AstraZeneca China President by law enforcement [1]. - It is asserted that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased shares of AZN during the specified class period are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is February 21, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - AstraZeneca PLC is under investigation for potential securities fraud and unlawful business practices, with implications for its senior executives [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca, focusing on possible securities fraud or unlawful business practices by the company and its executives [1]. - A fraud investigation into AstraZeneca has expanded to include several Chinese government agencies, implicating numerous senior executives [2]. Group 2: Market Reaction - Following the news of the fraud investigation, AstraZeneca's American depositary receipt (ADR) price dropped by $5.16, or 7.22%, closing at $66.27 per ADR on November 5, 2024 [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Johnson & Johnson (JNJ) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the subcutaneous (SC) formulation of Rybrevant (amivantamab) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutation. The C ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=126295&from=3 CLASS PERIOD: February 23, ...

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.07 per share, reflecting an increase of 46.6% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 18.8%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a compan ...